Related references
Note: Only part of the references are listed.First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Joshua K. Sabari et al.
CLINICAL CANCER RESEARCH (2022)
Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
Amin H. Nassar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mechanisms of Resistance to KRASG12C Inhibitors
Victoria Dunnett-Kane et al.
CANCERS (2021)
P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
S. Ramalingam et al.
Journal of Thoracic Oncology (2021)
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2021)
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Martin Sebastian et al.
LUNG CANCER (2021)
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
M. Reck et al.
ANNALS OF ONCOLOGY (2021)
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease
Alexander Spira et al.
LUNG CANCER (2021)
Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
Markus Y. Wu et al.
CANCERS (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Wanyuan Cui et al.
LUNG CANCER (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
M.L. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2020)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
Personalized therapy for lung cancer: Striking a moving target
Suchita Pakkala et al.
JCI INSIGHT (2018)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
MP Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)